IBS - Irritable Bowel Syndrome Clinical Trial
Official title:
Fecal Bile Acids, Fecal Short Chain Fatty Acids and the Intestinal Microbiota in Patients With Irritable Bowel Syndrome (IBS) and Control Volunteers: Diet Challenge
Verified date | June 2024 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to study the relationship between the bile acids, short chain fatty acids and bacteria within the intestines. The hypothesis is that changes in the bacterial composition of the stool are associated with the differences in bile acids and short chain fatty acids in patients having irritable bowel syndrome compared to healthy individuals.
Status | Terminated |
Enrollment | 31 |
Est. completion date | July 31, 2023 |
Est. primary completion date | July 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Patients with IBS, ages 18-65 fulfilling Rome IV criteria and asymptomatic controls with no prior history of GI disease or symptoms. - Participants should be on a stable and consistent diet regimen and should not be following an extreme diet intervention such as gluten-free or a low FODMAP diet at the time of study participation. Exclusion Criteria: - Participants with microscopic/lymphocytic/collagenous colitis, inflammatory bowel disease, celiac disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled thyroid disease, history of liver disease or history of elevated AST/ALT > 2.0x the upper limit of normal - Prior radiation therapy of the abdomen or abdominal surgeries except for C-section, tubal ligation, vaginal hysterectomy and appendectomy or cholecystectomy, > 6 months prior to study initiation. - Ingestion of any prescription, over the counter, or herbal medications which can affect GI transit or study interpretation (e.g. opioids, narcotics, anticholinergics, norepinephrine reuptake inhibitors, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, bile acid sequestrants) within 6 months of study initiation for asymptomatic volunteers or within 2 days before study initiation for IBS patients. Rescue therapy to facilitate stool collection will be permitted where needed. - Any females who are pregnant or trying to become pregnant or breast-feeding - Antibiotic usage within 3 months prior to study participation - Prebiotic or probiotic usage within the 2 weeks prior to study initiation - Regular use of tobacco products within the past 6 months. |
Country | Name | City | State |
---|---|---|---|
United States | Indiana University | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Indiana University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | 24-hour diet (food intake) recall | Optional 24-hour dietary intake will be submitted using web-based Automated Self-Administered Dietary Assessment Tool developed by the National Cancer Institute (https://epi.grants.cancer.gov/asa24/). | 30 to 90 days | |
Primary | Total fecal bile acids | Stool samples will be collected over 2 days for measurement of fecal bile acids (µmol/48h) by high performance liquid chromatography-mass spectometry | 48 hours | |
Primary | Total fecal short chain fatty acids | Stool samples will be collected for measurement of measurement of short chain fatty acids (µg/mg) by liquid chromatography-mass spectrometry | 48 hours | |
Primary | Individual fecal short chain fatty acids | Stool samples will be collected for measurement of measurement of short chain fatty acids (µg/mg) by liquid chromatography-mass spectrometry | 48 hours | |
Primary | Fecal microbial population | Stool samples will be be collected from participants for nucleic acid extraction, 16S allele PCR and sequencing to measure microbial communities and profiles of specimens | 48 hours | |
Primary | Fecal inulin | Fecal inulin content will be measured using short acid hydrolysis and high-performance liquid chromatography | 48 hours | |
Secondary | Percent primary fecal bile acids | Stool samples will be collected over 2 days for measurement of fecal bile acids (µmol/48h) by high performance liquid chromatography-mass spectrometry. | 48 hours | |
Secondary | Stool characteristics | Stool characteristics will be measured using a 4 day bowel diary | 4 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05118243 -
Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance
|
N/A | |
Completed |
NCT04422327 -
The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome
|
Phase 1/Phase 2 | |
Recruiting |
NCT05178017 -
Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
|
N/A | |
Completed |
NCT05197413 -
Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms
|
N/A | |
Completed |
NCT04905524 -
Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)
|
N/A | |
Recruiting |
NCT06297785 -
Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS)
|
N/A | |
Recruiting |
NCT05874830 -
The Optimal Route of Fecal Microbiota Transplantation for Irritable Bowel Syndrome
|
N/A | |
Active, not recruiting |
NCT04723056 -
Zemedy Application for Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT05565612 -
Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT03131414 -
The IMAGINE-SPOR CIHR Chronic Disease Network
|
||
Completed |
NCT03333291 -
Fecal Transplantation in Patients With IBS
|
N/A | |
Completed |
NCT03449628 -
L. Casei DG® in Patients With Irritable Bowel Syndrome.
|
N/A | |
Recruiting |
NCT06215222 -
Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
|
||
Completed |
NCT05016596 -
Postprandial Lipids in IBS and Nutritional Treatment
|
N/A | |
Recruiting |
NCT04760353 -
The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT06426745 -
Split-dose Versus Single-dose Bowel Preparation for Colonoscopy
|
N/A | |
Recruiting |
NCT04217733 -
Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
|
Phase 3 | |
Completed |
NCT03178877 -
The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors
|
N/A | |
Recruiting |
NCT05990764 -
Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS)
|
N/A | |
Completed |
NCT03948854 -
Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients
|
N/A |